217 related articles for article (PubMed ID: 25527468)
1. Limited access to drugs for resistant tuberculosis: a call to action.
Bélard S; Janssen S; Osbak KK; Adegnika AA; Ondounda M; Grobusch MP
J Public Health (Oxf); 2015 Dec; 37(4):691-3. PubMed ID: 25527468
[TBL] [Abstract][Full Text] [Related]
2. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
3. TIMEBOMB revisited 10 years later: can we sustain progress or are we losing the war?
Reichman LB
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1377-82. PubMed ID: 24125437
[TBL] [Abstract][Full Text] [Related]
4. Time to put boots on the ground: making universal access to MDR-TB treatment a reality.
Keshavjee S; Farmer PE
Int J Tuberc Lung Dis; 2010 Oct; 14(10):1222-5. PubMed ID: 20843411
[No Abstract] [Full Text] [Related]
5. [Drug resistant tuberculosis].
Zwolska Z; Augustynowicz-Kopeć E
Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
[TBL] [Abstract][Full Text] [Related]
6. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
[TBL] [Abstract][Full Text] [Related]
7. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
Günther G; Gomez GB; Lange C; Rupert S; van Leth F;
Eur Respir J; 2015 Apr; 45(4):1081-8. PubMed ID: 25395035
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistant tuberculosis: trends and control.
Prasad R; Gupta N; Singh M
Indian J Chest Dis Allied Sci; 2014; 56(4):237-46. PubMed ID: 25962197
[TBL] [Abstract][Full Text] [Related]
9. Ethical issues in tuberculosis diagnosis and treatment.
Selgelid MJ; Reichman LB
Int J Tuberc Lung Dis; 2011 Jun; 15 Suppl 2():9-13. PubMed ID: 21740653
[TBL] [Abstract][Full Text] [Related]
10. 'Universal' access for MDR-TB limited without the involvement of the private sector.
Pinto L; Udwadia Z
Int J Tuberc Lung Dis; 2011 Jun; 15(6):851; author reply 851-2. PubMed ID: 21575312
[No Abstract] [Full Text] [Related]
11. Programmes and principles in treatment of multidrug-resistant tuberculosis.
Mukherjee JS; Rich ML; Socci AR; Joseph JK; Virú FA; Shin SS; Furin JJ; Becerra MC; Barry DJ; Kim JY; Bayona J; Farmer P; Smith Fawzi MC; Seung KJ
Lancet; 2004 Feb; 363(9407):474-81. PubMed ID: 14962530
[TBL] [Abstract][Full Text] [Related]
12. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
[TBL] [Abstract][Full Text] [Related]
13. The re-emergence of tuberculosis.
Porter JD; McAdam KP
Annu Rev Public Health; 1994; 15():303-23. PubMed ID: 8054087
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
Ahmad S; Mokaddas E
Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
[TBL] [Abstract][Full Text] [Related]
15. 'I'm fed up': experiences of prior anti-tuberculosis treatment in patients with drug-resistant tuberculosis and HIV.
Furin J; Isaakidis P; Reid AJ; Kielmann K
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1479-84. PubMed ID: 25517815
[TBL] [Abstract][Full Text] [Related]
16. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
Fears R; Kaufmann S; Ter Meulen V; Zumla A;
Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
Wright A; Zignol M; Van Deun A; Falzon D; Gerdes SR; Feldman K; Hoffner S; Drobniewski F; Barrera L; van Soolingen D; Boulabhal F; Paramasivan CN; Kam KM; Mitarai S; Nunn P; Raviglione M;
Lancet; 2009 May; 373(9678):1861-73. PubMed ID: 19375159
[TBL] [Abstract][Full Text] [Related]
19. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era.
Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S
Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
Chan ED; Strand MJ; Iseman MD
Clin Infect Dis; 2009 Mar; 48(5):e50-2. PubMed ID: 19191632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
